Long Ideas - PropThink will host an expert interview on Thursday, April 11 (details below) to discuss the intellectual property (IP) position on Zerenex, Keryx Biopharmaceutical’s (KERX) late-stage phosphate … Continue Reading
Read NowLong Ideas - Navidea Biopharmaceuticals (NAVB) delivered a surprise to investors with earlier-than expected top-line interim results from the company’s NEO3-06 trial, which demonstrated Lymphoseek’s ability to identify … Continue Reading
Read NowLong Ideas - Since our report on Alexion Pharmaceuticals (ALXN) in early December, shares are virtually flat; outperformance through mid-January has been replaced by underperformance as expectations of … Continue Reading
Read NowLong Ideas - The spotlight has been on Astex Pharmaceuticals (ASTX) in the last month, and as investors have taken notice of the oncology developer, shares have rallied … Continue Reading
Read NowLong Ideas - Since our last report on ViroPharma (VPHM), shares of the Exton, Pennsylvania-based company have risen by just under 11%. While positive returns are always welcome, … Continue Reading
Read NowLong Ideas - As we wrote last week, Endo Health’s (ENDP) newly appointed CEO and former Valeant (VRX) operating star Rajiv De Silva is on the road with … Continue Reading
Read NowLong Ideas - Acquiring non-dilutive capital is always encouraging for a development-stage biotech company, and investors should take note when a company improves its balance sheet without hurting … Continue Reading
Read Now